MRT68921: Precision Dual ULK1/2 Autophagy Kinase Inhibition in Preclinical Research

Executive Summary: MRT68921 is a potent, selective inhibitor of ULK1 and ULK2, the serine/threonine kinases essential for autophagy initiation (IC₅₀: 2.9 nM for ULK1, 1.1 nM for ULK2) [product]. It robustly blocks ATG13 phosphorylation and LC3 flux, established markers of autophagy, in wild-type but not mutant ULK1 (M92T) cells [DOI]. MRT68921 exhibits >80% inhibitory activity against certain off-target kinases (TBK1/IKK, AMPK-related), but LKB1 knockout studies show ULK1 is its primary autophagy-relevant target [DOI]. The inhibitor is water- and ethanol-insoluble but dissolves in DMSO at ≥2.18 mg/mL with warming and sonication; it is supplied as a hydrochloride salt and recommended for storage at -20°C [product]. No in vivo or clinical data are available; MRT68921 is strictly for preclinical use [internal].

Biological Rationale

Autophagy is a conserved catabolic process where cells degrade and recycle cytoplasmic constituents to maintain homeostasis, especially under stress [Park et al., 2023]. The process is tightly regulated by serine/threonine kinases ULK1 and ULK2, which initiate autophagosome formation. ULK1 is activated or inhibited by upstream signals such as mTORC1 and AMPK, orchestrating autophagy in response to nutrient status. Recent studies reveal that, contrary to earlier models, AMPK directly inhibits ULK1 during energy stress, restraining autophagy induction but preserving the autophagy machinery for recovery [Park et al., 2023]. Targeted inhibition of ULK1/2 is a powerful approach for dissecting autophagy signaling and its role in disease models.

Mechanism of Action of MRT68921

MRT68921 is a small-molecule inhibitor that binds to the ATP-binding pockets of ULK1 and ULK2, blocking their kinase activity. This blockade prevents phosphorylation of downstream substrates such as ATG13, a hallmark event for autophagy initiation. In cell-based assays, MRT68921 effectively suppresses ATG13 phosphorylation and LC3 conversion (LC3-I to LC3-II), markers of autophagy flux [DOI]. The compound’s selectivity has been validated by resistance in cells expressing the ULK1 M92T mutant, which is insensitive to MRT68921. Notably, although MRT68921 also inhibits TBK1/IKK and several AMPK-related kinases (>80% inhibition), functional evidence from LKB1 knockout mouse embryonic fibroblasts (MEFs) indicates that these kinases are not the primary mediators of MRT68921-induced autophagy suppression [DOI]. Thus, MRT68921 enables precise and acute inhibition of the ULK1/2-driven autophagy pathway.

Evidence & Benchmarks

• MRT68921 inhibits ULK1 with an IC₅₀ of 2.9 nM and ULK2 with 1.1 nM in biochemical kinase assays (https://www.apexbt.com/mrt68921.html).
• Selective blockade of ATG13 phosphorylation and LC3 flux is observed in wild-type but not ULK1 M92T mutant cells, confirming on-target action (https://doi.org/10.1038/s41467-023-38401-z).
• MRT68921 inhibits TBK1/IKK and AMPK-related kinases by >80% in in vitro panels, but these effects are not responsible for autophagy inhibition in LKB1 knockout MEFs (https://doi.org/10.1038/s41467-023-38401-z).
• Compound is insoluble in water/ethanol, but dissolves at ≥2.18 mg/mL in DMSO with mild warming and sonication; supplied as hydrochloride salt (https://www.apexbt.com/mrt68921.html).
• No in vivo or human clinical data available; all findings are restricted to preclinical models and cell culture (https://www.apexbt.com/mrt68921.html).

This article extends the mechanistic detail of "MRT68921: Precision Autophagy Inhibition via Dual ULK1/2" by incorporating recent AMPK-ULK1 axis discoveries (Park et al., 2023), clarifying the compound’s true specificity. It also updates "MRT68921: Dual ULK1/2 Inhibitor Transforming Autophagy Research" by benchmarking selectivity using genetic knockout assays rather than only biochemical panels.

Applications, Limits & Misconceptions

MRT68921 is recommended for preclinical research aiming to dissect autophagy signaling, particularly in workflows studying autophagy initiation and flux. Its high affinity and selectivity make it suitable for acute pharmacological blockade of ULK1/2 in cell-based and biochemical assays. However, its off-target inhibition profile requires careful interpretation in experiments where TBK1/IKK or AMPK-related kinases may also be relevant. MRT68921 is not suitable for in vivo or clinical applications, and its DMSO-only solubility necessitates appropriate vehicle controls.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: MRT68921 is selective for ULK1/2 and a limited set of kinases; it does not broadly inhibit all serine/threonine kinases.
• Not effective in ULK1 M92T mutants: Cells expressing this mutant are resistant, confirming on-target action but limiting use in certain engineered lines.
• No in vivo validation: The compound lacks pharmacokinetic, toxicity, or efficacy data in animal models or humans.
• Solubility constraints: Insoluble in water/ethanol; improper vehicle use can cause precipitation or inconsistent dosing.
• Not a tool for mTOR inhibition: MRT68921 does not target mTOR; its effects are specific to the ULK1/2-initiated autophagy pathway.

Workflow Integration & Parameters

MRT68921 is supplied as a hydrochloride salt, molecular weight 434.58, chemical formula C₂₅H₃₄N₆O·xHCl. For cell culture experiments, dissolve in DMSO at concentrations ≥2.18 mg/mL with gentle warming and ultrasonic treatment. Store aliquots at -20°C for stability. Use vehicle-matched controls to account for DMSO-related effects. Recommended readouts include ATG13 phosphorylation status (immunoblot or immunofluorescence) and LC3 flux (Western blot, immunofluorescence, or flow cytometry). For genetic validation, include ULK1 mutant (M92T) or knockout lines as negative controls. For advanced integration and strategic guidance, see "Unraveling the AMPK-ULK1 Axis"—this article provides additional best-practice recommendations for translational workflows.

Conclusion & Outlook

MRT68921 stands as a premier, validated dual ULK1/2 kinase inhibitor for preclinical autophagy research. Its robust efficacy in blocking canonical autophagy markers, selectivity confirmed through genetic and kinase panel assays, and compatibility with standardized cell-based workflows make it essential for dissecting autophagy signaling. Future studies should address its in vivo characteristics and explore the translational potential for therapeutic autophagy modulation. For up-to-date specifications and ordering, see the MRT68921 product page.